Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H27N3O5 |
Molecular Weight | 449.499 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N(CC2=C1C=CC=C2OCC3=CC=C(CN4CCOCC4)C=C3)[C@H]5CCC(=O)NC5=O
InChI
InChIKey=IXZOHGPZAQLIBH-NRFANRHFSA-N
InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
CC-220 is a potent cereblon modulating agent that displays anti-proliferative, pro-apoptotic and immunomodulatory activity on sensitive and resistant multiple myeloma cell lines. CC-220 is currently under clinical investigation for systemic lupus erythematosus and multiple myeloma as a single agent, or in combination with dexamethasone in patients who may have previously been exposed to pomalidomide. Comparable to other Cereblon-binding agents, ex vivo treatment of CC-220 on B-cells, T-cells, and monocytes leads to the degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). followed by disruption of the multiple myeloma promoting c-Myc/IRF4 axis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q96SW2 Gene ID: 51185.0 Gene Symbol: CRBN Target Organism: Homo sapiens (Human) Sources: http://www.bloodjournal.org/content/128/22/1591 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02773030
0.3 mg for 21 days of a 28-day cycle
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
665718
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
||
|
NCI_THESAURUS |
C308
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
67335295
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
C129048
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
DE-06
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
DB12101
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
1323403-33-3
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
8V66F27X44
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
300000025973
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY | |||
|
10632
Created by
admin on Sat Dec 16 10:40:43 GMT 2023 , Edited by admin on Sat Dec 16 10:40:43 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)